Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Interest & Investment Income (2016 - 2025)

China Pharma Holdings' Interest & Investment Income history spans 16 years, with the latest figure at $213.0 for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 84.04% year-over-year to $213.0; the TTM value through Dec 2025 reached $2003.0, down 69.84%, while the annual FY2025 figure was $2003.0, 69.84% down from the prior year.
  • Interest & Investment Income reached $213.0 in Q4 2025 per CPHI's latest filing, down from $294.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $6655.0 in Q1 2022 to a low of $213.0 in Q4 2025.
  • Average Interest & Investment Income over 5 years is $1451.8, with a median of $1157.0 recorded in 2022.
  • Peak YoY movement for Interest & Investment Income: soared 1539.16% in 2022, then crashed 85.76% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $1412.0 in 2021, then decreased by 28.97% to $1003.0 in 2022, then surged by 152.24% to $2530.0 in 2023, then tumbled by 47.23% to $1335.0 in 2024, then plummeted by 84.04% to $213.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Interest & Investment Income are $213.0 (Q4 2025), $294.0 (Q3 2025), and $422.0 (Q2 2025).